 WALTHAM, MA ACCESSWIRE October 9, 2019 EyeGate Pharmaceuticals, Inc. EYEG EyeGate or the Company, a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization for its corneal wound repair pivotal study using the Ocular Bandage Gel OBG eye drop. The study enrolled a total of 250 patients requiring corneal wound repair following photorefractive keratectomy PRK surgery. The enrollment process included a formal screening to determine suitability for the procedure, followed by surgery and subsequent randomization into either the OBG or standard-of-care group. 